Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Naloxone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 01, 2019
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Naloxone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 01, 2019
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buprenorphine
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Buprenorphine is a Controlled Substance drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pain, Postoperative.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 18, 2017
Lead Product(s) : Buprenorphine
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Fentanyl Sublingual Spray for the Treatment of Moderate to Severe Post-Operative Pain
Details : Fentanyl is a Controlled Substance drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pain.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 27, 2016
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Recipient : University of Chicago
Deal Size : Inapplicable
Deal Type : Inapplicable
Cannabidiol and Emotional Stimuli
Details : Cannabidiol is a Controlled Substance drug candidate, which is currently being evaluated in clinical studies for the treatment of Substance-Related Disorders.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 15, 2016
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Recipient : University of Chicago
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Recipient : University of California, Los Angeles
Deal Size : Inapplicable
Deal Type : Inapplicable
Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers
Details : Cannabidiol is a Controlled Substance drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Pain.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 26, 2016
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Recipient : University of California, Los Angeles
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fentanyl
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Fentanyl Sublingual Spray in Opioid Naive Participants
Details : Fentanyl is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 29, 2015
Lead Product(s) : Fentanyl
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buprenorphine
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain
Details : Buprenorphine is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pain.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 18, 2015
Lead Product(s) : Buprenorphine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparative Bioavailability of Dronabinol Oral Solution in Healthy Volunteers
Details : This drug candidate is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 16, 2015
Lead Product(s) : Undisclosed
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fentanyl
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Recipient : MD Anderson Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea
Details : Fentanyl is a Controlled Substance drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 05, 2015
Lead Product(s) : Fentanyl
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Recipient : MD Anderson Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
